PROCESSA PHARMACEUTICALS, INC. Processa Pharmaceuticals, Inc. announced that it has named Steven Cha, M.D. as Senior Vice President of Clinical Research. In this newly created position, Dr. Cha?s experience as an oncologist as well as in oncology drug development will be important additions to Processa. Dr. Cha has nearly two decades of drug development experience through global approval and commercialization of drugs in hematological and solid tumor indications including romiplostim (first-in-class thrombopoietin), blinatumomab (first-in-class bispecific T-Cell engager) and neratinib (HER2+ breast cancer).
Specifically, Dr. Cha has extensive experience in breast cancer drug development, ranging from early to late phase clinical trials. While at Puma Biotechnology, Dr. Cha was responsible for the global Phase 3 study in HER2+ breast cancer for the combination of neratinib and capecitabine (the NALA Study), which led to regulatory approval and commercialization of the drug. In addition, he has worked at various biotech and pharmaceutical companies, including Pfizer, on a wide spectrum of modalities and platforms in breast cancer research including NG-HER2 antibody-drug conjugates (ADC), gedatolisib, CDK 2/4/6 inhibitors, pan-CLK inhibitors and hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Further, his academic research at Stanford University School of Medicine included autologous blood and marrow transplantation in breast cancer patients. Dr. Cha has also worked on other solid tumor indications including pancreatic ductal adenocarcinoma, prostate cancer, head and neck squamous cell carcinoma, lung cancer and melanoma utilizing cell therapy (CAR-T, NK cell), immuno-oncology, ADC and a vaccine approach. Dr. Cha received his Bachelor of Science in Biochemistry and Cell Biology from the University of California, San Diego and his Medical Degree from Tufts University School of Medicine.
He subsequently completed his postgraduate and fellowship training in hematology, as well as blood and marrow transplant at the Stanford University School of Medicine.
